This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19) In this sense, the repositioning drugs for new indications can offer a better risk versus-reward trade-off when compared to other drug development strategies, given that it makes use of drugs whose safety profile are already understood Nonetheless, this approach allows healthcare professionals to promptly tackle the disease by investigating readily available drugs against it